undamentalytics Newsletter
Sign in

Pacira Biosciences, Inc. (PCRX) stock

Add to watchlist

Add holding +

NASDAQ: PCRX Nasdaq Pharmaceuticals Next results ~November 5, 2026

B Fundamentals grade

Pacira Biosciences, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$57

Cash-flow model

Base case. Range ~$42–$77 across our lower- and higher-growth cases (-0.3%–9.7% a year).

Price vs value

Undervalued

The price is below our entire value range; our base value is 57% above it.

Price used: $36.40, November 3, 2026

Pacira Biosciences, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 5 selling0 purchases and 17 sales by directors and officers, last 12 monthsInsider trades
  • Funds113 adding, 108 cuttingOf 40 active managers that changed their stake, 23 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Pacira Biosciences files

Where Pacira Biosciences stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $746m, up 5.7% on a year earlier, faster than the 4.6% growth a quarter earlier. Free-cash-flow margin rose to 24.1% from 16.6% a year earlier. Operating margin widened to 2.7% from -14.8%. The diluted share count is down 2.8% on a year earlier, which lifts each remaining share. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 3 of our 6 financial-health checks. Our cash-flow model value is $57.07 a share, against a share price of $36.38. At that price, our model says the market is pricing in cash flow shrinking about 2.6% a year for five years, slower than the 6.6% a year revenue growth it has delivered.

Source: 10-Q filed August 4, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Pacira Biosciences, Inc.'s trailing-twelve-month revenue grew 5.7% year on year, with a free-cash-flow margin of 24.1%. Where it stands out: change in share count of -2.8% ranks 8 of 62 pharmaceuticals companies we cover.

Our discounted-cash-flow model values the business at ~$57 per share in the base case (~$42–$77 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Revenue growth accelerating: TTM revenue growth rose to 5.7% (+1.1pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Priced below our value. The share price of $36.40 is 57% below our value per share of $57.
  • Margins widening. Operating margin is up 17.4 points on a year ago.
  • Strong cash generation. 24.1% of revenue turned into free cash flow, against a median of 10.1% for pharmaceuticals companies we cover.
  • Shrinking share count. Diluted shares fell 2.8% in a year, so each share owns more of the business.

Things to watch

  • High earnings multiple. The shares trade at 105 times the last 12 months' earnings, so expectations are demanding.
  • Volatile shares. Over the past year the shares showed annualised volatility of 57% and a beta of 0.1 against the S&P 500.
  • Heavily shorted. 15.3% of the shares available to trade are sold short (1.9 days of average volume to cover).
  • Estimates being cut. Analysts' consensus for next year's earnings per share has fallen 5.2% over 90 days.

Latest results: FY2026 Q2

Filed August 4, 2026
Earnings per share
$0.73 against an average estimate of $0.65: beat by 12.8%
Revenue
$192m, up 6.2% on a year earlier
Share reaction
-7.6% in the first session after the results on August 4, 2026, against +1.6% for the S&P 500
Next report
November 5, 2026; average EPS estimate $0.73

Pacira Biosciences' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-0.0%
  • 1 week-0.0%
  • 1 month+44.4%
  • This year+40.6%
  • 1 year+64.0%
  • 5 years-35.3%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$746M
Operating margin
2.7%
Net margin
2.0%
EPS (TTM, diluted)
$0.35

Growth

Revenue growth
+5.7%
Change in growth rate
+1.1 pts
Share count change
−2.8%

Cash

Free cash flow (TTM)
$180M
FCF margin
24.1%
Stock pay % of revenue
7.5%

Earnings

Last results
August 4, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Pacira Biosciences, Inc. valuation models and calculator

What the price is pricing in

The share price implies cash flow shrinking about 2.8% a year for five years.That is slower than the 6.6% a year revenue growth Pacira Biosciences has delivered.

  • Priced in-2.8%
  • Last 12 months5.7%
  • 3 years a year3.7%
  • 5 years a year6.6%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($36.40, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Buy12-month view
12-month price target
~$57
Price used
$36.40close November 3, 2026
Implied change
▲ +57%
Uncertainty
Medium

How we got here: a discounted-cash-flow model of Pacira Biosciences, Inc.'s free cash flow after stock-based pay with after-tax interest added back ($124M, FY2026 Q2 TTM), growing 3.9% and 4.7% in the next two years (forecasts, guidance and its record), then back to 4.7% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$42–~$77 ; that spread sets a 25% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Pacira Biosciences, Inc.'s free cash flow after stock-based pay ( $124M, FY2026 Q2 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Pacira Biosciences, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 7.8%: the 10-year Treasury yield (4.9%) plus a beta of 0.63 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$57 ~$42–$77 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$31 ~$32–$64 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$2.3 ~$1.0–$5.0 Left out: out of range vs price (0.06x)
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$48 ~$31–$57 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Pacira Biosciences, Inc. with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −26%
  • Revenue growth 5 points higher ▲ +34%
  • Free-cash-flow margin 1 point lower ▼ −4%
  • Last year's free-cash-flow margin change, if it persists ▲ +43%
  • Discount rate 1 point higher ▼ −15%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $42$58$80$108$145$192
8.5% $32$43$59$79$105$139
10% $25$34$46$62$82$107

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$76.79$32.30$45.65$43.02$45.30$59.84$60.17$38.61$33.74$18.84$25.88$36.40
Market value$3.2bn$1.2bn$1.8bn$1.8bn$1.9bn$2.6bn$2.7bn$1.8bn$1.8bn$871m$1.2bn$1.5bn
+ Net debt (− = net cash)$64m$73m$222m$158m$228m$363m$104m$585m$369m$309m$214m$157m
Enterprise value$3.2bn$1.3bn$2.0bn$1.9bn$2.1bn$3.0bn$2.8bn$2.4bn$2.1bn$1.2bn$1.4bn$1.7bn
Multiples
Price / sales 12.7x4.4x6.3x5.2x4.5x6.1x5.1x2.7x2.6x1.2x1.6x2.1x
Price / earnings n/m————18.0x65.4x112.9x41.8x—165.7x105.3x
Price / free cash flow —137.5x—51.2x31.2x66.6x34.4x15.6x12.6x4.9x8.5x8.6x
EV / EBITDA 154.6x——66.0x70.1x44.9x24.1x15.7x13.0xn/m12.5x22.2x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

55 /100

Moderate moat

How hard Pacira Biosciences's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 14 / 20

    Cash operating profit has been a median 10.9% of total assets over 10 years.

  • Pricing power 17 / 20

    Gross margin has been a median 73.9%, moving by 5.3 percentage points (standard deviation) across 10 years.

  • Durability 0 / 20

    Operating margin has been a median 4.8%; its worst year was -18.9%.

  • Cash conversion 18 / 20

    Free cash flow was positive in 10 of 10 years, at a median 16.5% of revenue.

  • Discipline 11 / 20

    The diluted share count fell 6.6% over five years; stock-based pay has been a median 8.1% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (60 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close. Analysts expect revenue of $183m and EPS of $0.73 (range $0.52 to $0.82) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $2.90 +9% $754m +4%
Next $3.46 +19% $790m +5%

Next year's EPS estimate has moved −5.2% in 90 days, across 9 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +0.7% on 90 days ago. In the last 30 days, 1 analyst raised Pacira Biosciences, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Pacira Biosciences, Inc., last 90 days
$2.80 $3.00 $3.20 $3.40 $3.60 $3.80 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $2.88 Current fiscal year, 60 days ago: $2.95 Current fiscal year, 30 days ago: $2.89 Current fiscal year, 7 days ago: $2.89 Current fiscal year, Now: $2.90 $2.90 Next fiscal year, 90 days ago: $3.65 Next fiscal year, 60 days ago: $3.49 Next fiscal year, 30 days ago: $3.44 Next fiscal year, 7 days ago: $3.44 Next fiscal year, Now: $3.46 $3.46

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $2.88$3.65
60 days ago $2.95$3.49
30 days ago $2.89$3.44
7 days ago $2.89$3.44
Now $2.90$3.46

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.65 $0.73 +12.8%
Mar 2026 $0.56 $0.60 +6.4%
Dec 2025 $0.90 $0.57 −37.0%
Sept 2025 $0.65 $0.70 +7.4%

Adjusted EPS as companies report it, against the average analyst estimate.

How our valuation uses these forecasts

Our cash-flow model grows Pacira Biosciences, Inc.'s revenue by +3.9% next year and +4.7% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+3.5%, weight 67%) and the company's own record (+4.7%, weight 33%) . How the weights are set.

Analyst recommendations

9 analysts, Oct 2026
Buy00%
Hold9100%
Sell00%

Monthly trend

  1. Oct 202699
  2. Sep 202614319
  3. Aug 202613217
  4. Jul 202612216

Counts of recommendations published by analysts covering Pacira Biosciences, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
15.3%
of tradable shares
Days to cover
1.89
at average volume
Short interest, 1 month
−44%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
1.3%
of shares
Employees
825
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +70.3%

$21.38 on October 31, 2025 to $36.40

ThenNowEffect
Revenue (last 12 months) $706m $746m +5.7%
P/S multiple 1.3x 2.1x +56.6%
Share count 44m 42m +2.9%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years +17.3%

$31.04 on November 3, 2023 to $36.40

ThenNowEffect
Revenue (last 12 months) $669m $746m +11.5%
P/S multiple 2.1x 2.1x −3.8%
Share count 46m 42m +9.4%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
PCRX+1%−36%−13%−44%+37%+41%
Industry peers (median)−20%−52%−14%−2%+7%−14%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
PCRX50%33%42%33%50%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
PCRX−39%−53%−45%−67%−23%−26%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 3, 2015: 86% from April 8, 2022 to August 9, 2024. Getting back needed a 598% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$19.16 – $36.42
From 52-week high
−0.1%
vs 50-day average
+24.2%
vs 200-day average
+46.1%
Volatility (1 year)
57%
Beta vs S&P 500
0.10

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±5.4%
After a week
6 up, 6 down
typical move ±9.2%
After a month
6 up, 6 down
typical move ±13.2%
Results releasedNext dayS&P 500 next day5 days21 days
August 4, 2026 −7.6% +1.6% −9.4% −1.3%
April 30, 2026 −2.8% +1.3% −6.0% −8.7%
February 26, 2026 −6.6% −1.0% −2.6% −2.5%
January 8, 2026 −9.5% +0.7% −20.6% −19.0%
November 6, 2025 +0.9% −1.0% +8.1% +11.8%
August 5, 2025 −2.4% +0.3% +8.2% +16.5%
May 8, 2025 −0.2% +0.6% +1.7% +1.0%
February 27, 2025 −5.6% −0.1% −6.4% −2.2%
January 10, 2025 +13.7% −1.4% +20.3% +46.7%
November 6, 2024 +2.4% +3.3% −4.8% +11.5%
July 30, 2024 +1.4% +1.1% +6.1% −26.8%
May 7, 2024 +11.9% +0.1% +16.3% +9.9%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How Pacira Biosciences, Inc.’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 2, 2026. Check the live chain at your broker before trading.

Cash-secured put

Not offered: fundamentals grade B (needs B+ or better).

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

Covered call

Not offered: no liquid call at or above our price target — the model says the upside is worth more than any listed strike.

For holders: sell a call at a strike at or above our fair value, so the shares are only sold at a price the model calls full value.

Collar

Not offered: the shares trade below our fair value: a collar caps upside the model expects.

For holders of a stock trading at or above our fair value: buy a put for a floor and sell a call to pay for it.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

Pacira Biosciences, Inc. in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Pacira Biosciences, Inc.
$650M $700M $750M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $665.7M Revenue (TTM), FY23 Q4: $675M Revenue (TTM), FY24 Q1: $681.8M Revenue (TTM), FY24 Q2: $690.3M Revenue (TTM), FY24 Q3: $695M Revenue (TTM), FY24 Q4: $701M Revenue (TTM), FY25 Q1: $702.8M Revenue (TTM), FY25 Q2: $705.8M Revenue (TTM), FY25 Q3: $716.8M Revenue (TTM), FY25 Q4: $726.4M Revenue (TTM), FY26 Q1: $734.9M Revenue (TTM), FY26 Q2: $746.2M $746.2M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $665.7M
FY23 Q4 $675M
FY24 Q1 $681.8M
FY24 Q2 $690.3M
FY24 Q3 $695M
FY24 Q4 $701M
FY25 Q1 $702.8M
FY25 Q2 $705.8M
FY25 Q3 $716.8M
FY25 Q4 $726.4M
FY26 Q1 $734.9M
FY26 Q2 $746.2M
Revenue growth, TTM YoY Pacira Biosciences, Inc.
0% 2% 4% 6% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 1.8% Revenue growth, TTM YoY, FY23 Q4: 1.2% Revenue growth, TTM YoY, FY24 Q1: 1.9% Revenue growth, TTM YoY, FY24 Q2: 3.1% Revenue growth, TTM YoY, FY24 Q3: 4.4% Revenue growth, TTM YoY, FY24 Q4: 3.9% Revenue growth, TTM YoY, FY25 Q1: 3.1% Revenue growth, TTM YoY, FY25 Q2: 2.3% Revenue growth, TTM YoY, FY25 Q3: 3.1% Revenue growth, TTM YoY, FY25 Q4: 3.6% Revenue growth, TTM YoY, FY26 Q1: 4.6% Revenue growth, TTM YoY, FY26 Q2: 5.7% 5.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 1.8%
FY23 Q4 1.2%
FY24 Q1 1.9%
FY24 Q2 3.1%
FY24 Q3 4.4%
FY24 Q4 3.9%
FY25 Q1 3.1%
FY25 Q2 2.3%
FY25 Q3 3.1%
FY25 Q4 3.6%
FY26 Q1 4.6%
FY26 Q2 5.7%
Operating margin (TTM) Pacira Biosciences, Inc.
-20% -10% 0% 10% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: 6.7% Operating margin (TTM), FY23 Q4: 13.0% Operating margin (TTM), FY24 Q1: 15.3% Operating margin (TTM), FY24 Q2: 13.4% Operating margin (TTM), FY24 Q3: -9.3% Operating margin (TTM), FY24 Q4: -10.5% Operating margin (TTM), FY25 Q1: -12.0% Operating margin (TTM), FY25 Q2: -14.8% Operating margin (TTM), FY25 Q3: 5.8% Operating margin (TTM), FY25 Q4: 2.6% Operating margin (TTM), FY26 Q1: 3.3% Operating margin (TTM), FY26 Q2: 2.7% 2.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 6.7%
FY23 Q4 13.0%
FY24 Q1 15.3%
FY24 Q2 13.4%
FY24 Q3 -9.3%
FY24 Q4 -10.5%
FY25 Q1 -12.0%
FY25 Q2 -14.8%
FY25 Q3 5.8%
FY25 Q4 2.6%
FY26 Q1 3.3%
FY26 Q2 2.7%
FCF margin (TTM) Pacira Biosciences, Inc.
15% 20% 25% 30% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 19.6% FCF margin (TTM), FY23 Q4: 20.7% FCF margin (TTM), FY24 Q1: 25.4% FCF margin (TTM), FY24 Q2: 26.8% FCF margin (TTM), FY24 Q3: 27.8% FCF margin (TTM), FY24 Q4: 25.5% FCF margin (TTM), FY25 Q1: 22.7% FCF margin (TTM), FY25 Q2: 16.6% FCF margin (TTM), FY25 Q3: 17.3% FCF margin (TTM), FY25 Q4: 18.8% FCF margin (TTM), FY26 Q1: 18.1% FCF margin (TTM), FY26 Q2: 24.1% 24.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 19.6%
FY23 Q4 20.7%
FY24 Q1 25.4%
FY24 Q2 26.8%
FY24 Q3 27.8%
FY24 Q4 25.5%
FY25 Q1 22.7%
FY25 Q2 16.6%
FY25 Q3 17.3%
FY25 Q4 18.8%
FY26 Q1 18.1%
FY26 Q2 24.1%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Pacira Biosciences took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $726M
  2. Cost of revenue $150M · 20.6%
  3. Gross profit $577M · 79.4%
  4. Research and development $117M · 16.1%
  5. Selling, general and admin $369M · 50.8%
  6. Other operating costs $71.4M · 9.8%
  7. Operating income $19.2M · 2.6%
  8. Income tax $9.8M · 1.4%
  9. Net income $7M · 1.0%

Shares of revenue. Source: Pacira Biosciences's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 15 15 16 39 86 198 249 276 287 337 421 430 542 667 675 701 726 746
Gross profit 3 2 −1 7 31 120 177 166 199 250 314 312 401 468 490 531 577 591
EBITDA −24 −19 −35 −44 −48 5 21 −19 −11 29 30 66 118 152 163 5 110 76
Operating income −29 −23 −39 −49 −53 −5 9 −32 −25 16 10 46 90 60 88 −73 19 20
Net income −32 −27 −43 −52 −64 −14 2 −38 −43 −0 −11 146 42 16 42 −100 7 15
Diluted EPS −$55.32 −$47.29 −$2.64 −$1.72 −$1.93 −$0.39 $0.04 −$1.02 −$1.07 −$0.01 −$0.27 $3.33 $0.92 $0.34 $0.89 −$2.15 $0.16 $0.35
Growth (year on year)
Revenue — −3.0% +7.7% +149.1% +118.9% +131.1% +26.0% +11.0% +3.7% +17.7% +24.8% +2.0% +26.0% +23.1% +1.2% +3.9% +3.6% +5.7%
EBITDA — — — — — — +329.8% −191.3% — — +3.4% +120.4% +78.8% +27.9% +7.7% −96.7% — —
Operating income — — — — — — — −438.7% — — −34.2% +342.3% +94.0% −33.3% +46.1% −183.7% — —
Net income — — — — — — — — — — — — −71.2% −62.1% +163.7% −337.3% — —
Diluted EPS — — — — — — — — — — — — −72.4% −63.0% +161.8% −341.6% — —
Margins
Gross margin 18.0% 15.7% −6.7% 17.8% 36.0% 60.8% 71.1% 60.2% 69.3% 74.3% 74.7% 72.7% 74.1% 70.1% 72.6% 75.7% 79.4% 79.2%
EBITDA margin −162.6% −128.0% −221.7% −111.7% −55.6% 2.5% 8.4% −6.9% −3.9% 8.6% 7.1% 15.4% 21.9% 22.7% 24.2% 0.8% 15.2% 10.2%
Operating margin −190.2% −155.9% −249.2% −126.1% −62.3% −2.6% 3.8% −11.6% −8.7% 4.7% 2.5% 10.8% 16.6% 9.0% 13.0% −10.5% 2.6% 2.7%
Net margin −211.3% −186.4% −276.2% −133.8% −74.7% −6.9% 0.7% −13.7% −14.9% −0.1% −2.6% 33.9% 7.8% 2.4% 6.2% −14.2% 1.0% 2.0%
Free-cash-flow margin −175.6% −217.3% −236.9% −226.1% −65.5% 1.8% −4.9% 3.2% −0.5% 10.2% 14.3% 9.1% 14.7% 17.3% 20.7% 25.5% 18.8% 24.1%
Cash flow
Cash from operations −21 −25 −31 −70 −44 27 28 33 18 49 71 77 126 145 155 189 152 188
Capital spending 6 7 6 18 12 23 40 25 19 15 10 38 46 30 15 11 15 8
Free cash flow −26 −32 −37 −88 −56 4 −12 9 −1 34 60 39 80 115 139 179 137 180
Stock-based pay 1 0 2 5 12 25 33 31 32 32 34 40 42 48 48 51 58 56
Free cash flow after stock pay −27 −32 −40 −93 −68 −21 −46 −23 −33 3 27 −1 38 67 92 128 79 124
Balance sheet
Cash 7 26 46 13 13 38 54 36 54 133 78 100 586 104 153 277 159 206
Total debt 0 25 26 25 120 120 119 109 276 291 306 463 690 689 522 585 372 363
Net debt (negative = net cash) −7 −1 −21 13 107 82 64 73 222 158 228 363 104 585 369 309 214 157
Diluted shares — — 16m 30m 33m 35m 41m 37m 40m 41m 42m 44m 46m 47m 52m 46m 45m 42m
Returned to shareholders
Buybacks — 0 — — — — — — — — — — — 0 0 25 148 148
Total returned — 0 — — — — — — — — — — — 0 0 25 148 148

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

3 of 6 checks passed · June 30, 2026
What it owns · $1.2bn
Short-term assets $615mLonger-term assets $629m
What it owes, and who funded it · $1.2bn
Short-term liabilities $122mLonger-term liabilities $450mShareholders' equity $672m
  • Short-term assets cover short-term liabilities $615m of assets due within a year against $122m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $615m short-term assets against $450m of longer-dated liabilities.
  • More cash than debt $206m of cash against $363m of debt.
  • Debt below 40% of shareholders' equity Debt is 54% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt $188m of operating cash flow against $363m of debt.
  • Operating profit covers interest at least five times over Operating income of $20m against $15m of interest.

From Pacira Biosciences, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q2 TTM
Buybacks (TTM)
$148M
Returned to shareholders
83%
of free cash flow
Buybacks, last 3 fiscal years
$173M
Diluted share count
−2.8%
year over year
Total shareholder yield
10.2%
dividends 0.0% + buybacks 10.2% of market value
R&D spending
16.3%
of revenue
Sales & admin spending
50.8%
of revenue
Days sales outstanding
65 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in pharmaceuticals
Last 12 months unless stated PCRX AMPH CORT TVTX EBS SUPN Median
Revenue, last 12 months $746m $730m $831m $651m $649m $865m $276m
Revenue growth, last 12 months 5.7% 1.0% 16.0% 49.4% −17.7% 26.9% 9.9%
Revenue growth, 3-year average 3.7% 10.5% 24.7% 71.3% −16.2% 12.3% 5.5%
Revenue growth, latest quarter 6.2% 5.4% 31.7% 36.2% −52.4% 18.0% 6.5%
Gross margin 79.2% 47.7% 98.3% 98.5% 48.4% 87.6% 62.0%
Operating margin 2.7% 15.7% 0.8% −20.5% −27.7% −5.7% −5.9%
Operating margin, 3-year average 0.4% 24.3% 12.5% −72.3% −8.5% −0.7% −7.4%
Net margin 2.0% 10.8% 6.6% −18.7% −40.2% −5.1% −7.3%
Cash from operations / revenue 25.2% 25.3% 13.2% 27.1% 30.8% 10.2% 10.2%
Free-cash-flow margin 24.1% 20.9% 12.9% 27.1% 29.0% 10.1% 8.6%
Free-cash-flow margin, 3-year average 22.5% 20.5% 19.9% −40.1% 13.8% 15.6% 7.4%
Stock pay / revenue 7.5% 4.0% 10.7% 11.2% 2.8% 4.1% 3.6%
Change in share count −2.8% −7.8% −2.2% −1.7% −0.6% 2.8% 1.9%

Median of all 75 companies we cover in pharmaceuticals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

75 pharmaceuticals companies
Measure Company Peer median Rank
Revenue growth Growth 5.7% 10.0% 44 of 74
Change in growth rate Growth +1.1pp -0.3pp 31 of 74
Gross margin Profitability 79.2% 59.8% 11 of 59
Operating margin Profitability 2.7% -5.9% 25 of 67
Net margin Profitability 2.0% -7.3% 32 of 75
Free-cash-flow margin Cash generation 24.1% 10.1% 13 of 74
Stock pay as % of revenue Cash generation 7.5% 3.6% 51 of 69
Long-term debt as % of assets Balance sheet 29.2% 23.8% 30 of 53
Change in share count Balance sheet -2.8% 1.5% 8 of 62
Days sales outstanding Balance sheet 65 days 72 days 22 of 59

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $723M 99.1% ▲ 3.7%
EXPAREL $575M 79.6% ▲ 4.8%
ZILRETTA $117M 16.1% ▼ 1.2%
Iovera $24.2M 3.3% ▲ 6.0%
Royalty $3.6M 0.5% ▼ 5.9%
Bupivacaine Liposome Injectable Suspension $6.9M 0.9% ▼ 5.6%

From Pacira Biosciences, Inc.'s 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$1.1B
Institutions reporting
250
Shares held vs prior quarter
▲ 0.9%
Positions opened / closed
31 / 24

Top buyers and sellers, Q2 2026: 113 institutions bought and 108 sold ; the biggest buyer was UBS Group AG (+358K shares) and the biggest seller Citadel Advisors LLC (−635K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $170M 6.7M 15.2% ▼ 0.4%
Doma Perpetual Capital Management LLC $70.5M 2.8M 6.3% 0.0%
Vanguard Portfolio Management LLC $61M 2.4M 5.5% ▼ 3.8%
Dimensional Fund Advisors LP $53.4M 2.1M 4.8% ▲ 2.1%
State Street Corp $52.3M 2.1M 4.7% ▲ 7.3%
D. E. Shaw & Co., Inc. $49.5M 2.0M 4.4% ▼ 1.6%
Renaissance Technologies LLC $44M 1.7M 3.9% ▼ 5.0%
Vanguard Capital Management LLC $42.9M 1.7M 3.8% ▼ 5.2%
Goldman Sachs Group Inc $38.7M 1.5M 3.5% ▼ 2.7%
Geode Capital Management, LLC $29.4M 1.2M 2.6% ▲ 1.3%
Morgan Stanley $29M 1.1M 2.6% ▼ 17.8%
American Century Companies Inc $25.8M 1.0M 2.3% ▲ 21.6%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Pacira Biosciences, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $2.8M 17 trades by 5 insiders · 100% under pre-set plans
Net ▼ $2.8M net selling
Insider Date Trade Shares Price Value
Riker Lauren Senior Vice President, Finance October 8, 2026 Sell pre-set plan 6,000 $36.32 $217,920
Slonin Jonathan Chief Medical Officer August 17, 2026 Sell pre-set plan 3,040 $23.23 $70,619
Riker Lauren Senior Vice President, Finance June 11, 2026 Sell pre-set plan 6,115 $23.50 $143,702
Williams Kristen Chief Administrative Officer June 4, 2026 Sell pre-set plan 10,259 $22.27 $228,468
Cross Shawn Chief Financial Officer April 23, 2026 Sell pre-set plan 12,941 $25.16 $325,596
Cross Shawn Chief Financial Officer April 22, 2026 Sell pre-set plan 1,500 $25.01 $37,515
Cross Shawn Chief Financial Officer April 21, 2026 Sell pre-set plan 2,845 $25.01 $71,153
Cross Shawn Chief Financial Officer April 20, 2026 Sell pre-set plan 7,714 $25.14 $193,930
Froimson Mark Director March 17, 2026 Sell 500 $21.81 $10,905
Slonin Jonathan Chief Medical Officer March 17, 2026 Sell pre-set plan 3,261 $22.82 $74,416
Williams Kristen Chief Administrative Officer February 2, 2026 Sell pre-set plan 13,137 $20.53 $269,703
Riker Lauren Senior Vice President, Finance February 2, 2026 Sell pre-set plan 4,000 $20.81 $83,240

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 10 trades and filings

No trades in Pacira Biosciences, Inc. disclosed in the last 12 months; 10 earlier trades on record.

  • Tom Malinowski(D-NJ 7):Purchase, $1,001 - $15,000, traded May 6, 2021, filed June 23, 2021
  • Tom Malinowski(D-NJ 7):Purchase, $1,001 - $15,000, traded April 20, 2021, filed June 12, 2021
  • Tom Malinowski(D-NJ 7):Purchase, $1,001 - $15,000, traded January 25, 2021, filed August 26, 2021

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

  • August 4, 2026
  • April 30, 2026
  • February 26, 2026
  • January 8, 2026
  • November 6, 2025
  • August 5, 2025

Recent SEC filings

Data status

When each part of this page on Pacira Biosciences, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Pacira Biosciences, Inc. in brief

What does Pacira Biosciences, Inc. do?
Pacira Biosciences, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
What is Pacira Biosciences, Inc.'s stock ticker?
Pacira Biosciences, Inc. trades under the ticker PCRX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Pacira Biosciences, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Pacira Biosciences, Inc. reported revenue of $746M, 5.7% higher than a year earlier, according to its SEC filings.
What is Pacira Biosciences, Inc.'s free cash flow?
Pacira Biosciences, Inc.'s free-cash-flow margin is 24.1% of revenue over the trailing twelve months, ranking 13 of the 74 pharmaceuticals companies we cover.
What is Pacira Biosciences, Inc.'s fair value (intrinsic value) per share?
Our discounted-cash-flow model of Pacira Biosciences, Inc.'s free cash flow after stock-based pay gives ~$57 per share in the base case, and ~$42–$77 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Pacira Biosciences, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Doma Perpetual Capital Management LLC and Vanguard Portfolio Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Pacira Biosciences, Inc. buying back stock, and does it pay a dividend?
Pacira Biosciences, Inc. spent $148M on share repurchases over the trailing twelve months, and its diluted share count fell 2.8% over the year.
What is Pacira Biosciences, Inc.'s market cap?
On November 2, 2026, Pacira Biosciences, Inc.'s market capitalisation was about $1.5B, with a price-to-earnings ratio of 105.3 and net debt of $157M. Market figures come from third-party market data and may be delayed.
How much debt does Pacira Biosciences, Inc. have?
Pacira Biosciences, Inc.'s debt-to-equity ratio is 54.0%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
Who are Pacira Biosciences, Inc.'s competitors?
In our Pharmaceuticals peer group, the companies closest to Pacira Biosciences, Inc. are Amphastar Pharmaceuticals, Inc., Corcept Therapeutics Inc, Travere Therapeutics, Inc., Emergent Biosolutions Inc. and Supernus Pharmaceuticals, Inc. The side-by-side comparison below sets their revenue, margins and growth against Pacira Biosciences, Inc.'s.
Are insiders buying or selling Pacira Biosciences, Inc. stock?
Over the last 12 months, Pacira Biosciences, Inc.'s directors and officers reported 0 open-market purchases and 17 sales on Form 4. The insider trading page charts every trade.
When is Pacira Biosciences, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Pacira Biosciences, Inc. announces its own schedule.